Orange Book product · Brand (NDA)
IZERVAY
AVACINCAPTAD PEGOL SODIUM
At a glance
Aug 04, 2023
Approved
Brand (NDA)
Application
Not listed
TE code
6
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Aug 04, 2023
2 yr 11 mo ago
Today
Patent 8236773 expires
Listed method-of-use patent (U-3673) expiration.
Nov 11, 2026
in 5 mo
Patent 7579456 expires
Listed drug substance patent expiration.
Feb 14, 2027
in 8 mo
Patent 9617546 expires
Listed drug substance patent expiration.
Feb 14, 2027
in 8 mo
Patent 11273171 expires
Listed method-of-use patent (U-3673) expiration.
Jul 11, 2034
in 8 yr 2 mo
Patent 11491176 expires
Listed method-of-use patent (U-3673) expiration.
Jul 11, 2034
in 8 yr 2 mo
Patent 12016875 expires
Listed method-of-use patent (U-3673) expiration.
Jul 11, 2034
in 8 yr 2 mo
Pharmaceutical detail
Active ingredient
AVACINCAPTAD PEGOL SODIUM
Strength
EQ 2MG BASE/0.1ML (EQ 2MG BASE/0.1ML)
Dosage form
SOLUTION
Route
INTRAVITREAL
TE code
Not listed
Application
NDA 217225
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
Listed patents (6)
| Patent | Expires | In | Type |
|---|---|---|---|
| 8236773 | Nov 11, 2026 | in 5 mo | U-3673 |
| 7579456 | Feb 14, 2027 | in 8 mo | Substance |
| 9617546 | Feb 14, 2027 | in 8 mo | SubstanceU-3673 |
| 11273171 | Jul 11, 2034 | in 8 yr 2 mo | U-3673 |
| 11491176 | Jul 11, 2034 | in 8 yr 2 mo | U-3673 |
| 12016875 | Jul 11, 2034 | in 8 yr 2 mo | U-3673 |
